These results corroborate findings by Theodoraki et al. [121], where EV-PDL1 can serve as a diagnostic biomarker for predicting the effectiveness of therapy, as well as a new strategy to enhance T-cell-mediated immunotherapy against SCLC cancers. The gene discussed is CD274; the disease is cancer.